We reviewed 2019's top developments in Canadian life sciences IP and regulatory law in our highlights article.  Below were our top 10 reads:

#1 Update on biosimilars in Canada – October 2019

#2 Federal Court of Appeal requires PMPRB to re-determine whether patent 'pertains to' Galderma's DIFFERIN

#3 Amgen not precluded by invalidity decision under pre-amended PMNOC Regulations from litigating same patent under amended regulations 

#4 Canada releases final amendments to Patented Medicines Pricing Regulations; in force July 1, 2020

#5 Project Orbis enables concurrent regulatory approval of LENVIMA and KEYTRUDA combination therapy in Canada, U.S. and Australia

#6 Amended PMNOC Regulations: Second Anniversary Update

#7 Federal Court issues two interlocutory decisions in section 8 pregabalin case

#8 Orders of prohibition relating to polymorphic form patent for PRISTIQ upheld on appeal

#9 Federal Court of Appeal confirms obviousness finding in section 8 bortezomib action against Teva

#10 Eli Lilly granted leave to add new cause of action of direct infringement of "composition for use" claims, absent allegation of direct infringement by patients

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.